EXEL Nasdaq · Cancer medicines

Exelixis

Filings read on 20 November 2026

Revenue 2016: $191m2025: $2.3bn

Fit to the checklist
76.9 of 100

Counted on the 13 of 15 questions that could be answered from the filings. A second reader, working blind from the same quotes, arrived at 76.4 with 11 answered.

did not qualify: the bar is 9013 of 15 answered

A study note on how the company fits a fixed list of questions. Not a view on the shares, not a recommendation. How the marks are made

Position heldThe author holds no shares in this company. Stated on 21 November 2026.

01Quiet leadership

70 of 100 2 of 3 answered
Question 1.1

The chief executive credits others and owns the misses

Could not assess

The last two letters to shareholders and what the chief executive says alongside results.

How all 12 companies answered this

There are no earnings call transcripts and only one letter to shareholders. The chief executive thanks 'the Exelixis team' in a 2023 release, but no miss owned with a cause was found.

Found in the filings, but not enough to settle a mark:

I’d like to thank the Exelixis team for all their hard work and continued dedication toward advancing our mission to help cancer patients recover stronger and live longer.

Question 1.2

The chief executive grew up inside the company

5 of 5

The biography in the proxy statement.

How all 12 companies answered this

Morrissey joined Exelixis in February 2000 and became chief executive in July 2010. That is over ten years inside the company first.

Michael M. Morrissey, Ph.D., has served as a director and as Exelixis’ President and Chief Executive Officer since July 2010.

Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000, including serving as President of Research and Development from January 2007 to July 2010.

Question 1.3

No restructuring theatre

2 of 5

Restructuring programmes, company-wide rebrands and strategy overhauls in ten years of annual reports.

How all 12 companies answered this

Two programs fall inside the ten years: the January 2024 restructuring, which cut about 175 employees (13% of headcount), and the corporate reorganization plan of August 2025. The 2014 restructuring falls outside.

In August 2025, our Board of Directors authorized, and we implemented, a corporate reorganization plan (the 2025 Plan) to reorganize our workforce and close our office located in King of Prussia, Pennsylvania.

In January 2024, our Board of Directors authorized, and we implemented, a corporate restructuring plan (the 2024 Plan) to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities.

02People before plans

67 of 100 3 of 3 answered
Question 2.1

A real system for developing people

3 of 5

The people section of the annual report and the proxy statement.

How all 12 companies answered this

The annual report names the Exelixis Leadership Foundations, a two-year program, but gives no numbers for participants, promotions or training. One layoff in 2024 is not a repeated cycle.

In 2024, we established the Exelixis Leadership Foundations, a comprehensive two-year leadership program designed exclusively to assist managers in achieving outcomes effectively.

For the past five years, our employee turnover has trended below the U.S. life sciences industry benchmark, with the exception of 2024, which reflected the impact of an organizational restructure.

Question 2.2

Executives stay

4 of 5

Filings that report officer departures over the last three years.

How all 12 companies answered this

Two named executive officers left: Amy Peterson (effective August 29, 2025) and Jeffrey Hessekiel (November 2025). Both are named in the March 2025 filing on awards to named executive officers.

Effective August 29, 2025, Amy C. Peterson, M.D., has concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer of the Company.

On November 4, 2025, Jeffrey Hessekiel, J.D., Executive Vice President and General Counsel of Exelixis, Inc. (the Company) notified the Company of his intention to resign from the Company, effective in November 2025, and he will cease serving in his role as General Counsel effective as of November 7, 2025.

Question 2.3

The best people on the biggest opportunities

3 of 5

Who runs the main growth area, and where they came from.

How all 12 companies answered this

No specific named leader was moved to run the main growth area. Haley has led Commercial since 2020, but no move to the growth area is shown.

No checked quote is on file for this question. The company's filings at sec.gov

03Narrow focus

80 of 100 3 of 3 answered
Question 3.1

Best in the world at something

4 of 5

Market position claims and the sources given for them.

How all 12 companies answered this

The company states that CABOMETYX was the number one TKI monotherapy in RCC as of the third quarter of 2025. That is the company's own claim, with no independent source for the share.

As of the third quarter 2025, in RCC, CABOMETYX® (cabozantinib) was the market leader as the number one TKI monotherapy and the most prescribed TKI in combination with immunotherapy (IO).

Question 3.2

The same business for a decade

5 of 5

The business description from ten years ago beside the latest one.

How all 12 companies answered this

The 2016 business description is of small molecule cancer therapies centred on cabozantinib. The latest describes an oncology company where cabozantinib sales are still the majority of revenue.

Exelixis, Inc. (“Exelixis,” “we,” “our” or “us”) is a biopharmaceutical company that discovers, develops and commercializes small molecule therapies for the treatment of cancer.

Our business focuses predominantly on the development and commercialization of cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases, in various tumor indications.

Question 3.3

A clear way of making money per unit

3 of 5

Whether management reports profit or revenue per customer, store, shipment or similar.

How all 12 companies answered this

The annual report gives a 16% rise in CABOMETYX units and a 1% rise in average net selling price. A measure per unit can be worked out from that, but none is reported.

The increase in net product revenues for the year ended December 31, 2025, as compared to 2024, was primarily related to a 16% increase in the number of CABOMETYX units sold reflecting continuing demand for CABOMETYX in combination with nivolumab as a first-line treatment of patients with advanced RCC, and demand for previously treated advanced NET and, to a lesser extent, a 1% increase in the average net selling price of CABOMETYX.

04Discipline and straight talk

100 of 100 2 of 3 answered
Question 4.1

Careful with capital

5 of 5

Arithmetic on ten years of figures reported to the SEC: the change in share count and debt against free cash flow.

How all 12 companies answered this

Arithmetic from SEC figures gives 5: share count down 11.4% in five years and no debt against free cash flow. The only deal with a stated cost, the $80 million Insilico licence, is far below a fifth of the company's value.

2016: 251mShares outstanding2025: 282m

Ten years of figures the company reported to the SEC. Its annual reports at sec.gov

Question 4.2

Faces bad news squarely

Could not assess

The worst quarter or year of the last five, and what management said next.

How all 12 companies answered this

The net loss of $(30.2) million in the fourth quarter of 2022 is identified, and the release names the research and development costs behind it. With no earnings calls, a fix stated on the next call cannot be checked.

Found in the filings, but not enough to settle a mark:

GAAP net income (loss) for the quarter ended December 31, 2022 was $(30.2) million, or $(0.09) per share, basic and diluted, as compared to GAAP net income of $95.2 million, or $0.30 per share, basic and $0.29 per share diluted, for the comparable period in 2021.

The increases in research and development expenses were primarily related to increases in license and other collaboration costs, personnel expenses, consulting and outside services costs, and clinical trial costs.

Question 4.3

Earnings backed by cash

5 of 5

Arithmetic: five years of free cash flow against reported profit, and whether results were ever restated.

How all 12 companies answered this

Over five years, free cash flow was 1.31 times net income, which gives a 5. The SEC filing list shows no restatement filing in the last ten years.

2016: $205mFree cash flow2025: $876m

Ten years of figures the company reported to the SEC. Its annual reports at sec.gov

05Steady compounding

73 of 100 3 of 3 answered
Question 5.1

Steady growth, year after year

5 of 5

Arithmetic: years of falling revenue out of the last ten.

How all 12 companies answered this

Revenue did not fall in any of the last ten years, which gives a 5.

2016: $191mRevenue2025: $2.3bn

Ten years of figures the company reported to the SEC. Its annual reports at sec.gov

Question 5.2

No pivots or short-lived programmes

1 of 5

Strategy statements across ten years of annual reports.

How all 12 companies answered this

Two or more programs were abandoned: XL495 was discontinued in May 2025, XB064 and XB033 were discontinued, and five in-licensing collaborations were ended under the 2024 plan.

In May 2025, based on early clinical data generated for XL495, we announced that we will discontinue further development of this program.

As part of our rational and disciplined approach to investment, we have decided to discontinue further development of the XB064 and XB033 programs.

Question 5.3

A widening lead

5 of 5

Arithmetic: operating margin in the last three years against the three before.

How all 12 companies answered this

Operating margin moved by +10.4 points between the two three-year periods, which gives a 5. The only market share data are the company's own claims of a rising share in RCC, which support the mark, so it was not adjusted.

2016: -14.7%Operating margin2025: 37.6%

Ten years of figures the company reported to the SEC. Its annual reports at sec.gov

One study
a month

A new company, every answer with its source. No tips, no alerts, no hurry.